Compare STRO & FLC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | STRO | FLC |
|---|---|---|
| Founded | 2003 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Trusts Except Educational Religious and Charitable |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 159.5M | 162.4M |
| IPO Year | 2018 | 2003 |
| Metric | STRO | FLC |
|---|---|---|
| Price | $8.76 | $15.47 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 14 | 0 |
| Target Price | ★ $44.69 | N/A |
| AVG Volume (30 Days) | ★ 291.0K | 20.3K |
| Earning Date | 11-12-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $38,419,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.72 | $15.33 |
| 52 Week High | $43.85 | $18.09 |
| Indicator | STRO | FLC |
|---|---|---|
| Relative Strength Index (RSI) | 35.40 | 42.88 |
| Support Level | $8.11 | $15.40 |
| Resistance Level | $10.77 | $16.15 |
| Average True Range (ATR) | 0.85 | 0.19 |
| MACD | 0.14 | -0.02 |
| Stochastic Oscillator | 17.01 | 9.46 |
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. Company's wholly-owned product candidate is STRO-004, a single homogeneous ADC directed against tissue factor which are developing for the treatment of solid tumors. The company also pipeline contains STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.
Flaherty & Crumrine Total Return Fund Inc is a diversified, closed-end investment management company. Its investment objective is to provide its common shareholders with a high current income. The fund's secondary investment objective is capital appreciation.